Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®


This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.

Full Title of Study: “Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2008


  • Biological: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
    • 0.5 mL, IM
  • Biological: BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
    • 0.5 mL, IM

Arms, Groups and Cohorts

  • Experimental: Adacel® Vaccine Group
  • Active Comparator: BOOSTRIX® Vaccine Group

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®
    • Time Frame: Day 0 to 7 post-vaccination
    • Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.
  • Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
    • Time Frame: Day 0 and 28 days post-vaccination
  • Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
    • Time Frame: Day 0 and 28 days post-vaccination
  • Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.
    • Time Frame: Day 0 and 28 days post-vaccination

Participating in This Clinical Trial

Inclusion Criteria

  • Aged 11 – 18 years of age at the time of vaccination in this trial – Signed Institutional Review Board (IRB)-approved informed assent / consent form. – Able to attend all scheduled visits and to comply with all trial procedures. – For a female, negative serum/urine pregnancy test. Exclusion Criteria:

  • Any condition which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine. – Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc) that is unstable or that might: – interfere with the ability to participate fully in the study; or – interfere with evaluation of the vaccine. – Known or suspected impairment of immunologic function. – Febrile illness within the last 72 hours or an oral temperature ≥ 100.4°F (≥ 38°C) at the time of inclusion. – History of documented tetanus, diphtheria or pertussis disease within the preceding 5 years. – Known or suspected receipt of a tetanus or diphtheria-containing vaccine within the preceding 2 years. – Known or suspected receipt of a pertussis-containing vaccine within the preceding 5 years. – Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other therapy expected to materially alter immune function within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. – Received any vaccine in the 21-day period prior to enrollment or scheduled to receive any vaccination after enrollment and prior to visit 2. – Suspected or known hypersensitivity to any of the vaccine components or to latex.

Gender Eligibility: All

Minimum Age: 11 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sanofi
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Director, Study Director, Sanofi Pasteur Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.